Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: a review on the basis of clinical trials

Review and cost analysis of chemotherapy-induced myelosuppression events in relapsed small cell lung cancer (SCLC) patients.

Authors : Beatriz García, Javier Gómez, Jorge Iglesias, Belén Citoler, Miriam Prades, Manuel Dómine.

Year: 2023.

Congress: Congreso ESMO 2023.

Download PDF Outside URL

Subscribe to Outcomes´10

Name *

E-mail *

Todos los campos marcados con un * son obligatorios

Responsible for the data: Outcomes'10, s.l.u., Purpose: Sending commercial communications. Legitimation: Art. 6.1 Consent of the interested party. Recipient: No data is transferred unless expressly authorised. You may exercise your rights on data protection (access, rectification, opposition, deletion, automated decisions, limitation of treatment, portability) by email at dpo@outcomes10.com. Data will be retained for the time necessary to fulfill its purpose and derived responsibilities by current regulations and the deadlines in the applicable regulations on archives and documentation. In any case, you can request the protection of the Spanish Data Protection Agency through its website www.aepd.es/. In addition, you can consult more information on the privacy policy

I have read and accepted the privacy policy